|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oeffinger KC, Fontham ET, Etzioni R,
Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR,
LaMonte SJ, et al: Breast cancer screening for women at average
risk: 2015 guideline update from the American Cancer Society. JAMA.
314:1599–1614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vu T and Claret FX: Trastuzumab: Updated
mechanisms of action and resistance in breast cancer. Front Oncol.
2:622012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scaltriti M, Rojo F, Ocaña A, Anido J,
Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, y Cajal S Ramon, et
al: Expression of p95HER2, a truncated form of the HER2 receptor
and response to anti-HER2 therapies in breast cancer. J Natl Cancer
Inst. 99:628–638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Browne BC, O'Brien N, Duffy MJ, Crown J
and O'Donovan N: HER-2 signaling and inhibition in breast cancer.
Curr Cancer Drug Targets. 9:419–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pillai RS: MicroRNA function: Multiple
mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CP, Sun ZL, Lu X, Wu WX, Guo WL, Lu
JJ, Han C, Huang JQ and Fang Y: miR-340 suppresses cell migration
and invasion by targeting MYO10 in breast cancer. Oncol Rep.
35:709–716. 2016.PubMed/NCBI
|
|
10
|
Wei P, Qiao B, Li Q, Han X, Zhang H, Huo Q
and Sun J: microRNA-340 suppresses tumorigenic potential of
prostate cancer cells by targeting high-mobility group
nucleosome-binding domain 5. DNA Cell Biol. 35:33–43. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang D, Qiu S, Ge R, He L, Li M, Li Y and
Peng Y: miR-340 suppresses glioblastoma multiforme. Oncotarget.
6:9257–9270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takeyama H, Yamamoto H, Yamashita S, Wu X,
Takahashi H, Nishimura J, Haraguchi N, Miyake Y, Suzuki R, Murata
K, et al: Decreased miR-340 expression in bone marrow is associated
with liver metastasis of colorectal cancer. Mol Cancer Ther.
13:976–985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mohammadi-Yeganeh S, Paryan M, Arefian E,
Vasei M, Ghanbarian H, Mahdian R, Karimipoor M and Soleimani M:
MicroRNA-340 inhibits the migration, invasion, and metastasis of
breast cancer cells by targeting Wnt pathway. Tumour Biol.
37:8993–9000. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cancer Genome Atlas Research Network, ;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42(Database issue): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goswami CP and Nakshatri H: PROGgeneV2:
Enhancements on the existing database. BMC Cancer. 14:9702014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahashi RU, Miyazaki H and Ochiya T: The
roles of microRNAs in breast cancer. Cancers (Basel). 7:598–616.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:pp.
3983–3988. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tomlinson IP: Mutations in normal breast
tissue and breast tumours. Breast Cancer Res. 3:299–303. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu
Z and You Y: hsa-mir-181a and hsa-mir-181b function as tumor
suppressors in human glioma cells. Brain Res. 1236:185–193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johnson CD, Esquela-Kerscher A, Stefani G,
Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
Shingara J, et al: The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gennarino VA, D'Angelo G, Dharmalingam G,
Fernandez S, Russolillo G, Sanges R, Mutarelli M, Belcastro V,
Ballabio A, Verde P, et al: Identification of microRNA-regulated
gene networks by expression analysis of target genes. Genome Res.
22:1163–1172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fiore D, Donnarumma E, Roscigno G, Iaboni
M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C,
Romano G, et al: miR-340 predicts glioblastoma survival and
modulates key cancer hallmarks through down-regulation of NRAS.
Oncotarget. 7:19531–19547. 2016.PubMed/NCBI
|
|
26
|
Huang K, Tang Y, He L and Dai Y:
MicroRNA-340 inhibits prostate cancer cell proliferation and
metastasis by targeting the MDM2-p53 pathway. Oncol Rep.
35:887–895. 2016.PubMed/NCBI
|
|
27
|
Morgan-Fisher M, Wewer UM and Yoneda A:
Regulation of ROCK activity in cancer. J Histochem Cytochem.
61:185–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan S, Jiang H, Fang S, Yin F, Wang Z, Jia
Y, Sun X, Wu S, Jiang T and Mao A: MicroRNA-340 inhibits esophageal
cancer cell growth and invasion by targeting phosphoserine
aminotransferase 1. Cell Physiol Biochem. 37:375–386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morgan-Fisher M, Wewer UM and Yoneda A:
Regulation of ROCK activity in cancer. J Histochem Cytochem.
61:185–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Newell-Litwa KA, Badoual M, Asmussen H,
Patel H, Whitmore L and Horwitz AR: ROCK1 and 2 differentially
regulate actomyosin organization to drive cell and synaptic
polarity. J Cell Biol. 210:225–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilkes DM, Xiang L, Lee SJ, Chaturvedi P,
Hubbi ME, Wirtz D and Semenza GL: Hypoxia-inducible factors mediate
coordinated RhoA-ROCK1 expression and signaling in breast cancer
cells. Proc Natl Acad Sci USA. 111:pp. E384–E393. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ding W, Tan H, Zhao C, Li X, Li Z, Jiang
C, Zhang Y and Wang L: MiR-145 suppresses cell proliferation and
motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour
Biol. 37:6255–6260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai SD, Chen JS, Xi ZW, Zhang LJ, Niu ML
and Gao ZY: MicroRNA-144 inhibits migration and proliferation in
rectal cancer by downregulating ROCK-1. Mol Med Rep. 12:7396–7402.
2015.PubMed/NCBI
|
|
34
|
Zheng M, Sun X, Li Y and Zuo W:
MicroRNA-145 inhibits growth and migration of breast cancer cells
through targeting oncoprotein ROCK1. Tumour Biol. 37:8189–8196.
2016. View Article : Google Scholar : PubMed/NCBI
|
